Septerna 
250 East Grand Avenue, Suite 65
South San Francisco, CA 94080

Archive for News

Nature Biotechnology: Septerna – making another run on GPCRs

Read More

Nature Reviews Drug Discovery: Setting GPCRs Free

Read More

Biopharma Dive: GPCR-targeting drugs: A renewed focus on a ubiquitous group of proteins

Read More

BioSpace: Top Life Sciences Startups to Watch in 2023

Read More

Fierce Biotech: Septerna emerges with $100M to spark ‘second golden age’ of prolific drug target GPCR with pioneer as co-founder

Read More

ENDPOINTS: A new Third Rock startup seeks a ‘second golden age’ of GPCR drug discovery based on Nobel laureate’s work

Read More